The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Background: Liquid biopsy, particularly through the analysis of circulating tumor DNA (ctDNA), represents a significant advancement in oncology. Unlike traditional tissue biopsies, ctDNA offers a minimally invasive, real-time approach to cancer management. It has demonstrated considerable potential in early cancer detection, monitoring of therapeutic responses, and assessing minimal residual disease (MRD) to predict recurrence. By enabling comprehensive molecular profiling through a simple blood test, ctDNA supports the core principles of precision oncology, facilitating more personalized and adaptive treatment strategies. Methods: In the following article we describe the recent developments focused on refining ctDNA detection assays to improve sensitivity and specificity. Advanced technologies, including next-generation sequencing (NGS) and digital PCR, are commonly employed. The integration of artificial intelligence (AI) and multi-omics approaches—such as combining genomic, epigenomic, and transcriptomic data—has further enhanced the analytical power of ctDNA assays. Results: Emerging evidence shows that ctDNA-based liquid biopsy enables dynamic, real-time tracking of tumor evolution and therapeutic resistance. Clinical studies have demonstrated its efficacy in detecting early-stage cancers, guiding treatment selection, and predicting relapse with higher accuracy than some conventional methods. Moreover, AI-enhanced algorithms have improved signal detection, allowing for more precise and earlier identification of actionable mutations and MRD. Conclusions: ctDNA analysis via liquid biopsy is poised to revolutionize cancer care by offering a non-invasive, precise, and adaptive tool for tumor characterization and monitoring. Although obstacles remain—particularly regarding assay sensitivity, standardization, and economic feasibility—ongoing technological innovations and multi-omics integration are rapidly advancing its clinical viability. With continued progress, ctDNA-based liquid biopsy is likely to become a cornerstone of routine oncology practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the management of mCRC, the use of liquid biopsy by analyzing ctDNA via NGS (Figure 4) has become a transformative tool for overcoming both intrinsic and acquired tumor resistance to EGFR antagonists, such as panitumumab and cetuximab.”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [83]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Analytes, such as the ctDNA, extracellular vesicles (EVs), cell-free RNAs (cfRNAs), circulating tumor cells (CTCs), tumor-associated microRNAs, and tumor-educated platelets, can be assessed using liquid biopsy [83].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [83]
The cited source says what the claim attributes to it.
In the citing paper
“Unlike traditional biopsies, which are invasive and pose risks, ctDNA provides a real-time view of the tumor’s evolution at the molecular level and treatment response [83].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [83]
The cited source says what the claim attributes to it.
In the citing paper
“However, there are several limitations, such as standardization, assay performance, economic feasibility, limited tumor shedding, restricted access to the bloodstream, and false negatives due to low shedding [10,83,84].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0573-8 · Cited by 1,409
Next-Generation Sequencing Technology: Current Trends and Advancements
Satam, H., Joshi, K., Mangrolia, U., Waghoo, S., Zaidi, G., Rawool, S., Thakare, R. P., Banday, S., Mishra, A. K., Das, G., et al. (2023) · Biology · doi:10.3390/biology12070997 · Cited by 1,299
Liquid biopsy in cancer: current status, challenges and future prospects
Ma, L., Guo, H., Zhao, Y., Liu, Z., Wang, C., Bu, J., Sun, T., & Wei, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02021-w · Cited by 712
Next-generation sequencing in liquid biopsy: cancer screening and early detection
Chen, M., & Zhao, H. (2019) · Human Genomics · doi:10.1186/s40246-019-0220-8 · Cited by 556
Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices
Malla, M., Loree, J. M., Kasi, P. M., & Parikh, A. R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02615 · Cited by 292
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance
Stejskal, P., Goodarzi, H., Srovnal, J., Hajdúch, M., van ’t Veer, L. J., & Magbanua, M. J. M. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01710-w · Cited by 278
Circulating tumor DNA: current challenges for clinical utility
Dang, D. K., & Park, B. H. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154941 · Cited by 224
Sánchez-Herrero, E., Serna-Blasco, R., Robado de Lope, L., González-Rumayor, V., Romero, A., & Provencio, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.943253 · Cited by 184
Nguyen, V. T. C., Nguyen, T. H., Doan, N. N. T., Pham, T. M. Q., Nguyen, G. T. H., Nguyen, T. D., Tran, T. T. T., Long, V. D., Phan, T. H., Jasmine, T. X., et al. (2023) · eLife · doi:10.7554/elife.89083 · Cited by 135
Research works printed but not linked: 1
- Chaudhry, S.E., and Zarmina, E. (2025). Liquid Biopsy: Techniques, Biomarker Insights, and Oncological Impact, Springer.
Cited by
Singh, N. K., Ahmad, F., & Husain, A. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156506 · Cited by 3
Non-Invasive Diagnosis of Early Breast Cancer: Current and Emerging Liquid Biopsy Biomarkers
Kotsifaki, A., Masoura, C.-R., Limogianni, G., Kalouda, G., Stathaki, M., & Armakolas, A. (2026) · Cancers · doi:10.3390/cancers18142344 · Cited by 2
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“Analytes, such as the ctDNA, extracellular vesicles (EVs), cell-free RNAs (cfRNAs), circulating tumor cells (CTCs), tumor-associated microRNAs, and tumor-educated platelets, can be assessed using liquid biopsy [83].”
InfluentialSabnis, N. A., Cooksey, L. C., Jayakumar, H., Mendez, M. M., Mathew, E., Petty, R. M., Ranjan, A. P., Colón-Pérez, L. M., Dickerman, R. D., Mathew, P. A., et al. (2026) · Brain Sciences · doi:10.3390/brainsci16050487 · Cited by 1
Genomic innovations in cancer prevention, diagnosis, prognosis and precision therapeutics
Ananda, H., Sahana, S. R., Murthy, S. R., Kunnath, A. N., Prashant, A., Kaifi, J. T., Kiran, P. K., & Suvilesh, K. N. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1828450 · Cited by 1
Metadata
- Authors
- Rouvinov, K., Naamneh, R., Yakobson, A., Najjar, W., Abu Amna, M., Soklakova, A., Abu Zeid, E. E. D., Brenner, R., Asla, M., Ghalion, F. A., Abu Juma’a, A., Meirovitz, A., & Shalata, W.
- Affiliations
- Ben-Gurion University of the Negev (IL)
- Goldman Medical School, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel
- Hadassah Medical Center (IL)
- Department of Oncology, The Emek Medical Centre, Afula 18341, Israel
- Wolfson Medical Center (IL)
- Corresponding author
- Shalata, Walid
- ORCID
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2026-02-09
- Volume
- 16
- Issue
- 4
- Pages
- 523
- ISSN
- 2075-4418 (ISSN-L)
- PMC
- PMC12938931
- OpenAlex
- W7128422134
- Cited by
- 14
- References
- 44
- Citations by year
- 2026: 14
- FWCI
- 11.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diagnostics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Screening and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- liquid biopsy, circulating tumor DNA, early cancer detection, minimal residual disease, treatment response monitoring, precision oncology, digital PCR, next-generation sequencing, multi-omics integration, treatment resistance, tumor recurrence prediction, actionable mutations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology. https://app.cochat.ai/papers/10.3390/diagnostics16040523
- The paper
- Rouvinov, K., Naamneh, R., Yakobson, A., Najjar, W., Abu Amna, M., Soklakova, A., Abu Zeid, E. E. D., Brenner, R., Asla, M., Ghalion, F. A., Abu Juma’a, A., Meirovitz, A., & Shalata, W. (2026). The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology. Diagnostics. https://doi.org/10.3390/diagnostics16040523
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


